kongre.net
Welcome to kongre.net

Speaker

Mitchell Shirvan

Chief Scientific and Development Officer, Silexion Therapeutics

Mitchell Shirvan, Chief Scientific and Development Officer at Silexion Therapeutics, spoke at 8th RAS-Targeted Drug Development Summit (Boston, United States of America, 8–10 Sept 2026) in the session “SIL204, an Isoform-Selective Pan-KRAS Silencing Stable siRNA with Dual-Delivery Administration for Pancreatic Cancer: Phase 2 Early Safety Findings & Supporting Preclinical Data”.

Conferences
1
Keynotes
0
Upcoming
0

Past appearances

More speakers at 8th RAS-Targeted Drug Development Summit

  • Luke Pase

    Chief Technology Officer, Anocca AB

  • Nagi Ayad

    Professor, Georgetown University

  • Stephanie Braun

    Executive Director & Head of Enzalutamide, Medical Affairs (US), Astellas Pharma

  • Silvia Coma

    Senior Director, Translational & Preclinical Research, Verastem, inc

  • Peter DeMuth

    Chief Scientific Officer, Elicio Therapeutics

  • Matthew Farren

    Senior Research, Pharmacology Investigator, Incyte Corporation

See all 32 speakers on the event page

This profile is built from conference programmes published on kongre.net. It has not been claimed or confirmed by Mitchell Shirvan, and it lists only the talks, sessions and presentations named in those programmes.

Is this you? Claim this profile — every request is read by a person before anything is linked.

To ask for a correction or for this profile to be removed, email [email protected].